Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Former Abbott Drug Unit Recalls Synthroid Again

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2013 | 09:36pm CEST

Abbott Laboratories' (>> Abbott Laboratories) former pharmaceutical unit, now spun off as AbbVie Inc. (>> AbbVie Inc), recently recalled more than 28,520 bottles of the thyroid-hormone replacement therapy Synthroid over a dose mix-up, marking the second recall of the drug in six months.

One lot of 150-microgram Synthroid tablets was recalled because one bottle was found to contain lower-dose, 75-microgram tablets, AbbVie spokesman Gregory Miley said Friday. The voluntary recall was initiated in early December as a precaution, he said.

The cause was a "manufacturing line clearance error," he said, and AbbVie has taken corrective action. The company isn't aware of any increase in patient complaints or adverse events associated with the label error.

AbbVie was spun off to Abbott shareholders as an independent company at the start of January. AbbVie assumed Synthroid's U.S. marketing rights, though Abbott Labs continues to market the drug outside the U.S.

In July, Abbott recalled three lots of Synthroid because some bottles had defects that could affect the stability of the tablets at the end of shelf life. More than 136,500 bottles of Synthroid were subject to that recall, though Abbott said a majority of them remained under Abbott's control and weren't shipped out.

Both Synthroid recalls were classified by the FDA as Class II, which is typically applied in situations where a product might cause a temporary health problem or pose only a slight threat of a serious health problem.

Synthroid is a synthetic thyroid hormone used by people with hypothyroidism, in which the thyroid gland doesn't produce enough natural thyroid hormone.

Abbott reported $461 million of global Synthroid sales for the first nine months of 2012.

AbbVie shares were recently down a penny at $33.61.

Write to Peter Loftus at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, AbbVie Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
04/28 ABBOTT LABORATORIES (NYSE : ABT) Files An 8-K Departure of Directors or Certain ..
04/28 ABBOTT LABORATORIES : Change in Directors or Principal Officers, Financial State..
04/28 ABBOTT LABORATORIES : Transcatheter Mitral Valve Replacement Market 2017 - Valte..
04/27 ABBOTT LABORATORIES : Trademark Application for "SIMILAC GO & GROW" Filed by Abb..
04/27 ABBOTT LABORATORIES : Trademark Application for "CHANGES THAT LAST A LIFETIME" F..
04/27 ABBOTT LABORATORIES : Investigators from Abbott Laboratories Have Reported New D..
04/27 ABBOTT LABORATORIES : An Application for the Trademark "ENSURE" Has Been Filed b..
04/27 ABBOTT LABORATORIES : ' Trademark Application for "LABS ARE VITAL" Filed
04/27 ABBOTT LABORATORIES : and Alere Amend Terms of Merger Agreement
04/27 ABBOTT LABORATORIES : Reports First-Quarter 2017 Results
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/28 3 REAL-WORLD CASE STUDIES : How Spinoffs Unlock Shareholder Value
04/28 RISK ARBITRAGE TODAY : Dutch Auction In CIT Group
04/27 My Dividend Growth Portfolio - Q1 2017 Summary
04/26 S&P 500 Dividend Aristocrats Top Gainers For April Are Chevron, Nucor & AbbVi..
04/26 Abbott launches nutrition drinks for surgery patients
Advertisement
Financials ($)
Sales 2017 26 357 M
EBIT 2017 5 879 M
Net income 2017 3 106 M
Debt 2017 18 313 M
Yield 2017 2,40%
P/E ratio 2017 24,54
P/E ratio 2018 18,96
EV / Sales 2017 3,56x
EV / Sales 2018 3,30x
Capitalization 75 410 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 48,1 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES13.62%75 410
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.78%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
More Results